UK Vision Strategy claims sight loss is set to double

Article

Sight loss could double in the UK by the year 2050, according to predictions from eye health service UK Vision Strategy.

Sight loss could double in the UK by the year 2050, according to predictions from eye health service UK Vision Strategy.

Currently, one in five people aged 75 years and above have developed sight loss, compared to one in two people aged 90 years and above. Experts from the eye care and sight loss divisions are planning to identify improvements in diagnosis and find better treatments to avoid the predicted significant increase.

The UK Vision Strategy is a segment of the World Health Organisation's VISION 2020 initiative, which aspires to eliminate sight loss by the year 2020.

Chairperson of the UK Vision UK Vision Strategy and Chief Executive of Royal National Institute of Blind People, Lesley-Anne Alexander said, "Looking after your eyes by having regular checks is just as important as monitoring your blood pressure or paying a routine visit to the dentist. Problem teeth can usually be repaired or replaced but with eyes, the solution is rarely so simple. Whatever your age or health situation, if you haven't had your eyes checked recently, take action now and you could well prevent sight loss problems in later life".

Chairperson of VISION 2020 UK Nick Astbury, said, " Losing your sight should never become a naturally accepted part of getting older. Over half of all sight loss in this country can be avoided if it is picked up early and treated. Taking regular exercise, eating a healthy diet and stopping smoking is also vital for keeping your eyes healthy".

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.